บรรณานุกรม

1. Shah AA, Hasan F, Ahmed S, Hameed A. Prevalence of extended-spectrum beta-lactamases in nosocomial and outpatients ( ambulatory). Pak J Med Sci 2003; 19: 187-191.

2. Vincent JL, Bihari DJ, Syter PM, Bruining HA, White J, Nicolas-Chanoin MH, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995; 274: 639-644

3. Nijssen S, Florijn A, Bonten MJM, Schmitz FJ, Verhoet J, Fluit A. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents. 2004; 24: 585-91.

4. Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type ß-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 2004; 48: 1249-1255.

5. Chia JH, Chu C, Su LH, Chiu CH, Kuo AJ, Sun CF, Wu TL. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M ß-lactamases of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in Taiwan. J Clin Microbiol 2005; 43: 4486-4491.

6. Ensor VM, Shahid M, Evans JT, Hawkey PM. Occurrence, prevalence and genetic environment of CTX-M ß-lactamases in Enterobacteriaceae from Indian hospitals. J Antimicrob Chemother 2006; 58: 1260-1263.

7. Black JA, Moland ES, Kenneth S. AmpC disk test for detection of plasmid-mediated AmpC ß-lactamases in Enterobacteriaceae lacking chromosomal AmpC ß-lactamases. J Clin Microbiol 2005; 43: 3110-3113.

8. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum ß-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.

9. Turner PJ. Extended-spectrum beta-lactamases. Clin Infect Dis 2005; 41: S273-5.

10. Antimicrobial resistance surveillance [internet]. The surveillance of antimicrobial resistance in Scotland (SARIS) programme; [cited 2006 Sep 13]. Available from :

http://www.show.scot.nhs.uk/scieh/infectious/hai/SSHAIP/Surveillance/ Surveillance_AMR.htm

11. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001; 7: 333-336.

12. Hanson ND. AmpC beta-lactamases: what do we need to know for the future?. J Antimicrob Chemother 2003; 52: 2-4.

13. Manchanda V, Singh NP. Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother 2003; 51: 415-418.

14. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14.


 
%d bloggers like this: